Qiagen maintained by Merrill at sell

Qiagen NV was maintained by Merrill Lynch analyst Erica Whittaker at a sell rating following second-quarter earnings. Merrill said Qiagen is trading at a significant premium to its U.S. peers in the research tools business and there seems to be significant downside risk to the current share price. Qiagen shares declined $0.21, or 1.61%, to close at $12.86 on volume of 164,393 shares versus the three-month running average of 149,070 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.